Publications

This video focuses on the Maternal and Infant-Focused Neonatal Abstinence Syndrome (NAS) Investment Program’s interventions that have improved care and reduced hospital length of stay, NICU admissions, and need for pharmacologic treatment for opioid-exposed newborns and their mothers.

The Maternal and Infant-Focused Neonatal Abstinence Syndrome (NAS) Investment Program tested interventions to improve quality of care for opioid-exposed newborns and their mothers. This report evaluates the impact of both the NAS investment program and of specific interventions.

This impact brief focuses on successful quality improvement interventions from the Maternal and Infant-Focused Neonatal Abstinence Syndrome (NAS) Investment Program for families impacted by opioid use disorder, including increasing non-pharmacologic interventions, optimizing pharmacologic treatment and hospital utilization, and improving access to wraparound treatments.

Poster presented at the AcademyHealth National Health Policy Conference in 2020, sharing findings on caring for infants with neonatal abstinence syndrome in a hospital setting in Massachusetts

Emerging innovations and promising outcomes from an HPC investment program

These profiles provide a high-level snapshot of Maternal and Infant-Focused Neonatal Abstinence Syndrome (NAS) Investment Program awardees, the care models they implemented, and the goals of their initiatives.

This one-pager summarizes the HCII Neonatal Abstinence Syndrome (NAS) Investment Program.